Arabic Arabic English English French French German German
dark

Inotrem Receives Approval to Expand Nangibotide Clinical Trial in Critically Ill COVID-19 Patients and Receives Additional Public Funding of €45 Million

Inotrem S.A., a biotechnology company specializing in the development of immunotherapies targeting the TREM-1 pathway, announces that it has obtained authorization to pursue the clinical development of nangibotide up to registration in COVID-19 patients from both the French and Belgian competent authorities. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Acutus Medical, Inc. Announces Proposed Public Offering of Common Stock

Next Post

Veteran AI and ML Leader from LG Electronics and Bosch Joins H1 as SVP of Data Science and Machine Learning

Related Posts
Total
0
Share